Johnson & Johnson (JNJ) Position Maintained by Cohen Capital Management Inc.
Cohen Capital Management Inc. maintained its position in Johnson & Johnson (NYSE:JNJ) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,924 shares of the company’s stock at the end of the second quarter. Johnson & Johnson makes up about 1.9% of Cohen Capital Management Inc.’s portfolio, making the stock its 15th largest position. Cohen Capital Management Inc.’s holdings in Johnson & Johnson were worth $7,795,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Lenox Wealth Advisors Inc. lifted its position in Johnson & Johnson by 0.6% during the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after acquiring an additional 5 shares during the period. Harel Insurance Investments & Financial Services Ltd. increased its holdings in shares of Johnson & Johnson by 241.0% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock valued at $149,000 after purchasing an additional 841 shares during the period. Ullmann Financial Group Inc. acquired a new position in shares of Johnson & Johnson in the first quarter valued at approximately $186,000. Taylor Wealth Management Partners increased its holdings in shares of Johnson & Johnson by 19.8% in the first quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock valued at $188,000 after purchasing an additional 250 shares during the period. Finally, Foundation Resource Management Inc. acquired a new position in shares of Johnson & Johnson in the first quarter valued at approximately $204,000. 65.90% of the stock is currently owned by hedge funds and other institutional investors.
Several analysts have recently commented on JNJ shares. UBS AG restated a “buy” rating and issued a $148.00 target price (up previously from $136.00) on shares of Johnson & Johnson in a research note on Wednesday, July 19th. Goldman Sachs Group, Inc. (The) cut shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and increased their price target for the stock from $125.00 to $130.00 in a report on Wednesday, September 20th. BMO Capital Markets reaffirmed a “buy” rating and issued a $145.00 price objective on shares of Johnson & Johnson in a report on Friday, September 1st. Alembic Global Advisors cut Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research report on Friday, July 21st. Finally, BidaskClub upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 17th. Five equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $134.79.
In other Johnson & Johnson news, VP Dominic J. Caruso sold 82,591 shares of the business’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the sale, the vice president now directly owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of the business’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the sale, the vice president now directly owns 230,342 shares in the company, valued at $30,667,733.88. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/10/04/johnson-johnson-jnj-position-maintained-by-cohen-capital-management-inc.html.
Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.56% during midday trading on Wednesday, hitting $132.84. 1,649,386 shares of the stock were exchanged. Johnson & Johnson has a one year low of $109.32 and a one year high of $137.08. The stock’s 50-day moving average price is $132.27 and its 200 day moving average price is $129.78. The stock has a market cap of $356.54 billion, a P/E ratio of 22.48 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The business had revenue of $18.84 billion for the quarter, compared to the consensus estimate of $18.94 billion. During the same period last year, the firm posted $1.74 earnings per share. The firm’s quarterly revenue was up 1.9% compared to the same quarter last year. On average, analysts anticipate that Johnson & Johnson will post $7.18 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th were paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.54%. The ex-dividend date of this dividend was Friday, August 25th. Johnson & Johnson’s dividend payout ratio is 56.76%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.